These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 27364936)

  • 1. SPRINT: The Study Nephrologists Might Take With a Grain of Salt.
    Covic A; Apetrii M; Goldsmith D; Kanbay M
    J Clin Hypertens (Greenwich); 2016 Nov; 18(11):1185-1188. PubMed ID: 27364936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood Pressure Goals in Patients with CKD: A Review of Evidence and Guidelines.
    Chang AR; Lóser M; Malhotra R; Appel LJ
    Clin J Am Soc Nephrol; 2019 Jan; 14(1):161-169. PubMed ID: 30455322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In the Wake of Systolic Blood Pressure Intervention Trial: New Targets for Improving Hypertension Management in Chronic Kidney Disease?
    Tyson CC; Coffman TM
    Nephron; 2017; 135(4):287-290. PubMed ID: 28161697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterogeneity of treatment effect in SPRINT by age and baseline comorbidities: The greatest impact of intensive blood pressure treatment is observed among younger patients without CKD or CVD and in older patients with CKD or CVD.
    Rostomian AH; Tang MC; Soverow J; Sanchez DR
    J Clin Hypertens (Greenwich); 2020 Sep; 22(9):1723-1726. PubMed ID: 33460256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The results of SPRINT study from the point of nephrology].
    Monhart V
    Vnitr Lek; 2016; 62 Suppl 6():55-57. PubMed ID: 28124932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generalizability of SPRINT-CKD cohort to CKD patients referred to renal clinics.
    Minutolo R; De Nicola L; Gallo C; Chiodini P; Provenzano M; Conte G; Garofalo C; Borrelli S;
    J Nephrol; 2019 Jun; 32(3):429-435. PubMed ID: 30673974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dipping Status, Ambulatory Blood Pressure Control, Cardiovascular Disease, and Kidney Disease Progression: A Multicenter Cohort Study of CKD.
    Borrelli S; Garofalo C; Gabbai FB; Chiodini P; Signoriello S; Paoletti E; Ravera M; Bussalino E; Bellizzi V; Liberti ME; De Nicola L; Minutolo R
    Am J Kidney Dis; 2023 Jan; 81(1):15-24.e1. PubMed ID: 35709922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is the KDIGO Systolic Blood Pressure Target <120 mm Hg for Chronic Kidney Disease Appropriate in Routine Clinical Practice?
    Dasgupta I; Zoccali C
    Hypertension; 2022 Jan; 79(1):4-11. PubMed ID: 34784720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Intensive Blood Pressure Lowering on Kidney Tubule Injury in CKD: A Longitudinal Subgroup Analysis in SPRINT.
    Malhotra R; Craven T; Ambrosius WT; Killeen AA; Haley WE; Cheung AK; Chonchol M; Sarnak M; Parikh CR; Shlipak MG; Ix JH;
    Am J Kidney Dis; 2019 Jan; 73(1):21-30. PubMed ID: 30291012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blood Pressure Targets in CKD: Lessons Learned from SPRINT and Previous Observational Studies.
    Gosmanova EO; Kovesdy CP
    Curr Cardiol Rep; 2016 Sep; 18(9):88. PubMed ID: 27448402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Precision Medicine for Hypertension Management in Chronic Kidney Disease: Relevance of SPRINT for Therapeutic Targets in Nondiabetic Renal Disease.
    Ruzicka M; Burns KD; Hiremath S
    Can J Cardiol; 2017 May; 33(5):611-618. PubMed ID: 28365055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BP Measurement in Clinical Practice: Time to SPRINT to Guideline-Recommended Protocols.
    Drawz PE; Ix JH
    J Am Soc Nephrol; 2018 Feb; 29(2):383-388. PubMed ID: 29051347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood Pressure Variability Predicts Adverse Events and Cardiovascular Outcomes in Chronic Kidney Disease: A Post-Hoc Analysis of the SPRINT Trial.
    Mezue K; Goyal A; Pressman GS; Horrow JC; Rangaswami J
    Am J Hypertens; 2017 Dec; 31(1):48-52. PubMed ID: 28985328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KDOQI US Commentary on the 2021 KDIGO Clinical Practice Guideline for the Management of Blood Pressure in CKD.
    Drawz PE; Beddhu S; Bignall ONR; Cohen JB; Flynn JT; Ku E; Rahman M; Thomas G; Weir MR; Whelton PK
    Am J Kidney Dis; 2022 Mar; 79(3):311-327. PubMed ID: 35063302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modifying Effect of Statins on Fatal Outcomes in Chronic Kidney Disease Patients in the Systolic Blood Pressure Intervention Trial: A Post Hoc Analysis.
    Rivera M; Tamariz L; Suarez M; Contreras G
    Am J Nephrol; 2019; 49(4):297-306. PubMed ID: 30917364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implications of Blood Pressure Measurement Technique for Implementation of Systolic Blood Pressure Intervention Trial (SPRINT).
    Agarwal R
    J Am Heart Assoc; 2017 Feb; 6(2):. PubMed ID: 28159816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What is the ideal blood pressure goal for patients with stage III or higher chronic kidney disease?
    Khouri Y; Steigerwalt SP; Alsamara M; McCullough PA
    Curr Cardiol Rep; 2011 Dec; 13(6):492-501. PubMed ID: 21887524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypertension in chronic kidney disease after the Systolic Blood Pressure Intervention Trial: targets, treatment and current uncertainties.
    Kovesdy CP
    Nephrol Dial Transplant; 2017 Apr; 32(suppl_2):ii219-ii223. PubMed ID: 28201651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BP Targets in Hypertension: What Should We Do Now That SPRINT Is Out?
    Bhatt H; Ghazi L; Calhoun D; Oparil S
    Curr Cardiol Rep; 2016 Oct; 18(10):98. PubMed ID: 27566331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How Low Do We Go (in the Post-SPRINT Era)?
    Burgner A; Lewis JB
    Adv Chronic Kidney Dis; 2019 Mar; 26(2):110-116. PubMed ID: 31023444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.